Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Drug: RZ-001 Dose 1Drug: RZ-001 Dose 2Drug: RZ-001 Dose 3
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Rznomics, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT06695026
- Locations
- 🇰🇷
Gangnam Severance Hospital, Seoul, Korea, Republic of
🇰🇷Kangbuk Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Korea University Guro Hospital, Seoul, Korea, Republic of
Expanded Access Program for GBM Subjects
- Conditions
- Glioblastoma
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Rznomics, Inc.
- Registration Number
- NCT06676891
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Glioblastoma
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Rznomics, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT06102525
- Locations
- 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: RZ-001 Dose 1Drug: RZ-001 Dose 2Drug: RZ-001 Dose 3Drug: RZ-001 Dose 4
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Rznomics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05595473
- Locations
- 🇰🇷
Kyungpook National University Hospital, Deagu, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Seoul, Korea, Republic of